5-Amino-1MQ Research: What Published Studies Have Investigated

What is 5-Amino-1MQ?

What is 5-Amino-1MQ? It is a small-molecule, membrane-permeable inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). Chemically it is 5-amino-1-methylquinolinium — a methylquinolinium compound, and importantly not a peptide. It was first characterised as an NNMT inhibitor in a metabolic research context by Neelakantan et al. (2017, Biochemical Pharmacology), where it was studied in cell-culture and mouse models. That is a neutral molecular definition; the sections below describe what researchers examined, not effects in people. Because the published record specific to this molecule is thin and entirely preclinical, this page is written as an honest early-evidence explainer rather than a mechanism-of-benefit page.

Molecule properties

5-Amino-1MQ is built on a small-molecule methylquinolinium scaffold carrying a primary-amine substitution. In the source literature it is reported as membrane-permeable and, in the assays used, selective — Neelakantan et al. (2017) described that the methylquinolinium inhibitors did not inhibit related SAM-dependent methyltransferases or NAD+-salvage enzymes in those tests. In research catalogues it is supplied as a lyophilized powder and handled as a research chemical. These are molecule and chemistry facts only; this page gives no handling, reconstitution, or dosing guidance, and the compound is distinct from the peptide range Cellworks catalogues separately.

What NNMT is, and why researchers study inhibiting it

Neutral background first. NNMT catalyses the methylation of nicotinamide, using the methyl donor SAM (S-adenosylmethionine), and produces 1-methylnicotinamide (1-MNA). Because nicotinamide is a precursor in the NAD+ salvage pathway and SAM is the cell’s principal methyl donor, researchers have studied NNMT as a shared node connecting NAD+ metabolism and one-carbon / SAM metabolism. That places the enzyme at an interesting junction of two pathways, which is what makes it an active research target rather than any established therapy.

The target-validation context is worth stating plainly. Kraus et al. (2014, Nature) reported that antisense knockdown of NNMT in mouse adipose tissue was associated with protection against diet-induced obesity in that mouse model. That genetic-knockdown finding is what motivated the subsequent search for small-molecule NNMT inhibitors such as the methylquinolinium series. Reported accurately, this is a study that investigated NNMT knockdown in mice; it does not establish any effect in humans, and it is described here strictly as what researchers examined.

Mechanisms and findings researchers have examined

The 5-Amino-1MQ mechanism literature is small and centres on NNMT inhibition and the downstream NAD+/SAM biology. Each direction below is framed as what researchers examined in cells and mice, never as an effect directed at a reader:

• NNMT inhibition in adipocytes — Neelakantan et al. (2017) reported that, in cultured 3T3-L1 mouse adipocytes, methylquinolinium NNMT inhibitors reduced intracellular 1-MNA and were associated with higher intracellular NAD+ and SAM in those cell models.
• Adipocyte lipogenesis (cell model) — the same report described reduced lipogenesis in those cultured adipocyte models. This is an in-vitro observation in a cell line, not an outcome a reader would experience.
• Diet-induced-obese (DIO) mouse model — Neelakantan et al. (2017) reported, in high-fat-diet mice, changes in body weight, white-adipose mass, adipocyte size, and plasma cholesterol relative to vehicle controls in that model. These are presented as neutral study observations in mice, with no numbers directed at the reader and no implication of a human effect.
• Corroborating target work — Kannt et al. (2018, Scientific Reports) studied a different small-molecule NNMT inhibitor (JBSNF-000088) in mouse metabolic models, part of the same target-validation literature around the enzyme.

The section closes as the literature does: 5-Amino-1MQ has been characterised primarily in mouse and cell-culture models, and its mechanism centres on NNMT inhibition and the downstream NAD+/SAM biology. This is NNMT inhibitor research, reported as what was investigated rather than what was concluded about people, and each bullet names a pathway or model examined, not a benefit.

Research models in the literature

The models are preclinical only. On the cell side, cultured 3T3-L1 mouse pre-adipocytes and adipocytes; on the animal side, diet-induced-obese C57BL/6 mice maintained on a high-fat diet. Behind these sits the target-validation genetics lineage — the NNMT antisense-knockdown work in mice reported by Kraus et al. (2014), and review context on NNMT in NAD+/SAM metabolism, obesity and type 2 diabetes summarised by Liu et al. (2021, BioMed Research International).

It is worth stating plainly, and more than once: there is little published literature specific to 5-Amino-1MQ — essentially one direct primary paper plus the surrounding NNMT target-validation work — and there are no published human interventional, pharmacokinetic, or clinical-trial data. The body of evidence is early-stage and preclinical. Findings observed in cultured adipocytes or in high-fat-diet mice cannot establish outcomes in humans, and the fat-metabolism, adipose, and body-weight observations exist only in those animal and cell-culture models. They are described here as neutral research observations, never as an effect, benefit, or purpose for the reader.

5-Amino-1MQ in the context of NNMT / NAD+ research

Positioned within its research field, 5-Amino-1MQ sits as a research-focus node in NNMT and NAD+/SAM biology rather than as a standalone story. What makes NNMT an active research target is its position at the junction of the NAD+ salvage pathway and SAM-dependent methylation, which is why small-molecule inhibitors of the enzyme are studied alongside the broader NAD+ literature. For the related pathway context on the NAD+ precursor side, see NAD research; for other metabolic-research compounds studied in preclinical models, see SLU-PP-332 research and MOTS-c research. This is family and pathway context only — not stacking, combination, or use advice.

Research-grade sourcing and verification

For laboratory research use only, 5-Amino-1MQ is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation, with lot-level verification. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. This framing concerns quality and identity assurance for research use, not outcomes.

Frequently asked questions

Literature cited

1. Neelakantan H, Vance V, Wetzel MD, Wang HY, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ. “Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.” Biochemical Pharmacology. 2017;147:141–152. PMID: 29155147.
2. Kraus D, Yang Q, Kong D, Banks AS, Zhang L, Rodgers JT, Pirinen E, Pulinilkunnil TC, Gong F, Wang YC, Cen Y, Sauve AA, Asara JM, Peroni OD, Monia BP, Bhanot S, Alhonen L, Puigserver P, Kahn BB. “Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.” Nature. 2014;508(7495):258–262. PMID: 24670636.
3. Kannt A, Rajagopal S, Kadnur SV, et al. “A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders.” Scientific Reports. 2018;8:3660. PMID: 29483571.
4. Liu JR, Deng ZH, Zhu XJ, Zeng YR, Guan XX, Li JH. “Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes.” BioMed Research International. 2021;2021:9924314. PMID: 34368359.